Research graph
References from A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy. Local targets link to admitted publications; unresolved targets remain external evidence.
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience
10.1016/s0094-0143(05)70163-4 · 2001 · External reference
Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy
10.1002/cncr.28215 · 2013 · External reference
Unresolved reference
External reference
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
10.1056/nejmoa041318 · 2004 · External reference
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
10.1056/nejmoa040720 · 2004 · External reference
Combination of taxanes with radiation: Preclinical studies
1999 · External reference
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer
10.1016/s0090-4295(00)00858-x · 2000 · External reference
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy
10.1200/jco.2006.08.9607 · 2007 · External reference
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy
10.1001/jama.291.11.1325 · 2004 · External reference
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial
10.1016/s1470-2045(12)70560-0 · 2013 · External reference
Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: Preliminary results of a multicentre phase II trial
10.1016/j.radonc.2010.08.012 · 2010 · External reference
Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer
10.1111/j.1464-410x.2012.11536.x · 2012 · External reference
10.1186/1748-717x-9-24
10.1186/1748-717x-9-24 · 2014 · External reference
Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate
10.1200/jco.2004.02.001 · 2004 · External reference
Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma
10.1016/j.clgc.2013.11.019 · 2014 · External reference
Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10)
10.1016/j.urolonc.2007.04.003 · 2008 · External reference
Radiation Therapy Oncology Group 0521: A phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer
10.3816/cgc.2005.n.035 · 2005 · External reference
10.1200/jco.2015.33.18_suppl.lba5002
10.1200/jco.2015.33.18_suppl.lba5002 · External reference
A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy
10.1016/j.prro.2014.02.003 · 2014 · External reference
Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy
10.1016/j.ijrobp.2007.01.049 · 2007 · External reference
10.1200/jco.2010.28.15_suppl.9123
10.1200/jco.2010.28.15_suppl.9123 · External reference
10.1016/j.ijrobp.2014.06.019
10.1016/j.ijrobp.2014.06.019 · External reference
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer
10.1158/0008-5472.can-11-1417 · 2011 · External reference
Taxane mechanisms of action: Potential implications for treatment sequencing in metastatic castration-resistant prostate cancer
10.1016/j.eururo.2013.07.022 · 2014 · External reference
Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer
10.1158/0008-5472.can-09-1504 · 2009 · External reference
Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy
10.1016/j.ijrobp.2011.03.003 · 2012 · External reference
Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy
10.1016/j.prro.2013.05.008 · 2014 · External reference
